Skip to main content

Table 1 Demographic and baseline characteristics (All PsA ixekizumab-exposure safety population)

From: Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis

CharacteristicsAll-IXE treatment periods(N = 1118)
Age, years, mean (SD)49.5 (11.9)
Sex, n (%)
 Male517 (46.2)
 Female601 (53.8)
Race, n (%)
 White1056 (94.5)
 Asian39 (3.5)
 American Indian or Alaska Native9 (0.8)
 Multiple8 (0.7)
 Black or African American4 (0.4)
 Native Hawaiian or other Pacific Islander1 (0.1)
Weight, kg, mean (SD)86.31 (20.4)
BMI, kg/m2, mean (SD)29.95 (6.9)
Previous PsA systemic therapya, n (%)
 No prior treatment218 (19.5)
 Non-biologic only562 (50.3)
 Biologic only71 (6.4)
 Biologic and non-biologic267 (23.9)
Duration of PsA symptoms in years, mean (SD)9.71 (8.7)
  1. All-IXE treatment period defined as all patients who received ≥ 1 dose of IXE
  2. aSystemic therapy includes biologic (such as anti-TNF inhibitors) and non-biologic (such as cDMARDs, NSAIDs, and corticosteroids) medications that were used prior to the study entry
  3. bDMARDs biologic disease-modifying antirheumatic drugs, BMI body mass index, cDMARDs conventional disease-modifying antirheumatic drugs, IXE ixekizumab, N population size, n number in each group, NSAIDs non-steroidal anti-inflammatory drugs, PsA psoriatic arthritis, SD standard deviation